$117.78
0.23% today
Nasdaq, Feb 28, 04:48 pm CET
ISIN
US64125C1099
Symbol
NBIX

Neurocrine Biosciences, Inc. Stock price

$117.51
-30.68 20.70% 1M
-35.04 22.97% 6M
-18.99 13.91% YTD
-18.52 13.61% 1Y
+27.64 30.76% 3Y
+25.56 27.80% 5Y
+78.46 200.92% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.08 0.07%
ISIN
US64125C1099
Symbol
NBIX
Sector
Industry

Key metrics

Market capitalization $11.72b
Enterprise Value $11.14b
P/E (TTM) P/E ratio 35.71
EV/FCF (TTM) EV/FCF 19.99
EV/Sales (TTM) EV/Sales 4.73
P/S ratio (TTM) P/S ratio 4.97
P/B ratio (TTM) P/B ratio 4.51
Revenue growth (TTM) Revenue growth 24.81%
Revenue (TTM) Revenue $2.36b
EBIT (operating result TTM) EBIT $583.00m
Free Cash Flow (TTM) Free Cash Flow $557.20m
Cash position $1.08b
EPS (TTM) EPS $3.29
P/E forward 27.62
P/S forward 4.36
EV/Sales forward 4.15
Short interest 3.58%
Show more

Is Neurocrine Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Neurocrine Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

22x Buy
79%
6x Hold
21%

Analyst Opinions

28 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

Buy
79%
Hold
21%

Financial data from Neurocrine Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2,355 2,355
25% 25%
100%
- Direct Costs 58 58
0% 0%
2%
2,298 2,298
26% 26%
98%
- Selling and Administrative Expenses 980 980
13% 13%
42%
- Research and Development Expense 708 708
29% 29%
30%
610 610
47% 47%
26%
- Depreciation and Amortization 27 27
27% 27%
1%
EBIT (Operating Income) EBIT 583 583
48% 48%
25%
Net Profit 341 341
37% 37%
14%

In millions USD.

Don't miss a Thing! We will send you all news about Neurocrine Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neurocrine Biosciences, Inc. Stock News

Neutral
PRNewsWire
about 19 hours ago
SAN DIEGO , Feb. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line data from a Phase 4 study, KINECT-PRO™, demonstrating clinically meaningful and sustained effects of INGREZZA® (valbenazine) capsules on the physical, social and emotional impacts experienced by patients living with tardive dyskinesia (TD), irrespective of TD severity or underlying psy...
Neutral
PRNewsWire
3 days ago
SAN DIEGO , Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Chief Commercial Officer Eric Benevich will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 at 11:10 AM Eastern Time in Boston.
Neutral
PRNewsWire
7 days ago
SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program t...
More Neurocrine Biosciences, Inc. News

Company Profile

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Head office United States
CEO Kyle Gano
Employees 1,800
Founded 1992
Website www.neurocrine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today